BioClub Secures Tens of Millions RMB in Series A Funding Led by Share Investment

On April 29, Beike She officially announced the closing of its Series A financing round, amounting to tens of millions of RMB, led by Share Capital. Beike She had previously completed its Pre-A financing round in October last year, with Shanghai Dezhihe Investment as the investor.

Beike Society, established in 2014, is an innovation and entrepreneurship platform dedicated to “Internet + Healthcare.” Since its launch, the platform has brought together a large community of stakeholders in the healthcare entrepreneurship ecosystem by providing services spanning branding, media, events, incubation and acceleration programs, entrepreneurial camps, and investment and financing support.

Beike Society distinguishes itself as an innovation and entrepreneurship service platform dedicated to “Internet+” healthcare, encompassing the investment and incubation platforms Beike Fund and Beike Camp, as well as a B2B third-party service platform for healthcare startups based on SaaS and cloud services. To date, Beike Fund and Beike Camp have invested in and incubated nearly 30 healthcare ventures, including China’s largest community for pathologists and digital pathology platform, and Fenlan Medical, the founding entity of the first pathologist group in China.

It is understood that Beike She will also expand its overseas operational centers in Melbourne, Australia, and Silicon Valley, USA, focusing on investing in, nurturing, and introducing high-quality projects and teams in the broader health sector, thereby facilitating the localization of global entrepreneurial resources in China.

The lead investor in this financing round is Share Capital, a top-tier venture capital firm in China that focuses on early-stage investments in the healthcare and internet sectors. It has invested in over 100 projects. Share Capital’s healthcare portfolio includes numerous well-known companies such as BGI Group, Meinian Onehealth Healthcare, Buchang Pharma, iCarbonX, Genetron Health, JieNuoFei, Medprin Regenerative Medical Technologies, Focus Pharmaceutical, Hanbang Pharmaceutical, Changsen Pharmaceutical, Bianque Emergency Rescue, Huaxia Pathology Network, and Zhang Qiang Doctor Group.